In last trading session, TG Therapeutics Inc. (NASDAQ:TGTX) saw 1.57 million shares changing hands with its beta currently measuring 2.14. Company’s recent per share price level of $8.17 trading at $0.04 or 0.49% at ring of the bell on the day assigns it a market valuation of $1.24B. That closing price of TGTX’s stock is at a discount of -213.34% from its 52-week high price of $25.60 and is indicating a premium of 57.41% from its 52-week low price of $3.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.09 million shares which gives us an average trading volume of 2.64 million if we extend that period to 3-months.
For TG Therapeutics Inc. (TGTX), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 9 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.34 in the current quarter.
TG Therapeutics Inc. (NASDAQ:TGTX) trade information
Upright in the green during last session for gaining 0.49%, in the last five days TGTX remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $8.17 price level, adding 4.89% to its value on the day. TG Therapeutics Inc.’s shares saw a change of -57.00% in year-to-date performance and have moved -3.43% in past 5-day. TG Therapeutics Inc. (NASDAQ:TGTX) showed a performance of 51.86% in past 30-days. Number of shares sold short was 19.44 million shares which calculate 8.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $17.56 to the stock, which implies a rise of 53.47% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $40.00. It follows that stock’s current price would drop -389.6% in reaching the projected high whereas dropping to the targeted low would mean a gain of 51.04% for stock’s current value.
TG Therapeutics Inc. (TGTX) estimates and forecasts
Statistics highlight that TG Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 63.73% of value to its shares in past 6 months, showing an annual growth rate of 49.81% while that of industry is 2.60. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 47.70% in the current quarter and calculating 44.30% increase in the next quarter. This year revenue growth is estimated to rise 109.40% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.69 million for the same. And 5 analysts are in estimates of company making revenue of $11.67 million in the next quarter that will end on Dec 2022. Company posted $2.03 million and $2.32 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -16.70% while estimating it to be 402.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.50% during past 5 years.
TG Therapeutics Inc. is more likely to be releasing its next quarterly report between November 02 and November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
TG Therapeutics Inc. (NASDAQ:TGTX)’s Major holders
Insiders are in possession of 8.26% of company’s total shares while institution are holding 75.50 percent of that, with stock having share float percentage of 82.30%. Investors also watch the number of corporate investors in a company very closely, which is 75.50% institutions for TG Therapeutics Inc. that are currently holding shares of the company. State Street Corporation is the top institutional holder at TGTX for having 14.24 million shares of worth $60.5 million. And as of Jun 29, 2022, it was holding 9.80% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 13.02 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 8.96% of outstanding shares, having a total worth of $55.34 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 8.42 million shares of worth $49.83 million or 5.79% of the total outstanding shares. The later fund manager was in possession of 3.77 million shares on Jun 29, 2022, making its stake of worth around $16.04 million in the company or a holder of 2.60% of company’s stock.